CN117100833B - 一种调理肠道菌群的中药组合物及其制备方法和应用 - Google Patents
一种调理肠道菌群的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN117100833B CN117100833B CN202311281481.3A CN202311281481A CN117100833B CN 117100833 B CN117100833 B CN 117100833B CN 202311281481 A CN202311281481 A CN 202311281481A CN 117100833 B CN117100833 B CN 117100833B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 35
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title description 11
- 208000024891 symptom Diseases 0.000 claims abstract description 36
- 206010022000 influenza Diseases 0.000 claims abstract description 25
- 239000010231 banlangen Substances 0.000 claims abstract description 15
- 241001673966 Magnolia officinalis Species 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 12
- 241000218236 Cannabis Species 0.000 claims abstract description 11
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 4
- 241000220261 Sinapis Species 0.000 claims abstract description 4
- 239000003610 charcoal Substances 0.000 claims abstract description 4
- 235000004347 Perilla Nutrition 0.000 claims description 22
- 244000124853 Perilla frutescens Species 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 244000068988 Glycine max Species 0.000 claims description 12
- 235000010469 Glycine max Nutrition 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 235000006463 Brassica alba Nutrition 0.000 claims description 11
- 244000140786 Brassica hirta Species 0.000 claims description 11
- 235000011371 Brassica hirta Nutrition 0.000 claims description 11
- 241001522129 Pinellia Species 0.000 claims description 11
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 11
- 244000197580 Poria cocos Species 0.000 claims description 11
- 235000008599 Poria cocos Nutrition 0.000 claims description 11
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 11
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 11
- 235000008397 ginger Nutrition 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 235000013717 Houttuynia Nutrition 0.000 claims description 9
- 240000000691 Houttuynia cordata Species 0.000 claims description 9
- 244000042430 Rhodiola rosea Species 0.000 claims description 9
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 9
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 9
- 235000006751 Platycodon Nutrition 0.000 claims description 7
- 244000046146 Pueraria lobata Species 0.000 claims description 7
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229930189914 platycodon Natural products 0.000 claims description 7
- 240000003109 Persicaria chinensis Species 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 3
- 235000009120 camo Nutrition 0.000 claims description 3
- 235000005607 chanvre indien Nutrition 0.000 claims description 3
- 239000011487 hemp Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 244000111489 Gardenia augusta Species 0.000 claims 2
- 244000088415 Raphanus sativus Species 0.000 claims 2
- 240000001949 Taraxacum officinale Species 0.000 claims 2
- 244000273928 Zingiber officinale Species 0.000 claims 2
- 235000013399 edible fruits Nutrition 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 1
- 235000018958 Gardenia augusta Nutrition 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 206010011224 Cough Diseases 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 12
- 206010012735 Diarrhoea Diseases 0.000 abstract description 11
- 208000003251 Pruritus Diseases 0.000 abstract description 10
- 230000007803 itching Effects 0.000 abstract description 9
- 238000011084 recovery Methods 0.000 abstract description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 7
- 206010022437 insomnia Diseases 0.000 abstract description 7
- 206010019233 Headaches Diseases 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 6
- 206010047700 Vomiting Diseases 0.000 abstract description 6
- 230000036528 appetite Effects 0.000 abstract description 6
- 235000019789 appetite Nutrition 0.000 abstract description 6
- 231100000869 headache Toxicity 0.000 abstract description 6
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 5
- 206010010774 Constipation Diseases 0.000 abstract description 5
- 208000002173 dizziness Diseases 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 5
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 241000157835 Gardenia Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 241000712461 unidentified influenza virus Species 0.000 description 10
- 230000009385 viral infection Effects 0.000 description 10
- 241000220259 Raphanus Species 0.000 description 9
- 241000234314 Zingiber Species 0.000 description 9
- 210000003800 pharynx Anatomy 0.000 description 9
- 241000245665 Taraxacum Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241000894007 species Species 0.000 description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241001015933 Longibaculum Species 0.000 description 4
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000001528 Coronaviridae Infections Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241001464921 Phascolarctobacterium Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- HCOLPNRPCMFHOH-UHFFFAOYSA-N Prodigiosin Natural products CCCCCC1C=C(C=C/2N=C(C=C2OC)c3ccc[nH]3)N=C1C HCOLPNRPCMFHOH-UHFFFAOYSA-N 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- TWFGRJUTAULJPZ-USZBIXTISA-N prodigiosin Chemical compound N1=C(C)C(CCCCC)=C\C1=C/C1=NC(C=2[N]C=CC=2)=C[C]1OC TWFGRJUTAULJPZ-USZBIXTISA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 208000010603 vasculitis due to ADA2 deficiency Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种调理肠道菌群的中药组合物,属于中药技术领域。本发明中药组合物包括如下组分:枙子、淡豆豉、紫苏子、白芥子、莱服子、半夏、厚朴、茯苓、生姜、苏叶、蒲公英、鱼腥草、黄芩、桔梗、红景天、葛根、板蓝根、火麻仁、火炭母、陈皮、羌活。上述药味配伍之后共奏缓解流行感冒引起的失眠、胃痛、胃胀、头痛、头晕、食欲下降、咳嗽、恶心呕吐、咽痒咽痛、腹泻、便秘等症状,同时还具有调理流感恢复期患者肠道菌群的功效,最终达到治疗流感后遗症的效果。
Description
技术领域
本发明属于中药技术领域,具体涉及一种调理肠道菌群的中药组合物及其制备方法和应用。
背景技术
流行性感冒,是由流感病毒感染引起的一种急性呼吸道疾病。流感病毒感染最常见的症状是呼吸道症状,包括咳嗽,发烧,头痛,虚弱,通常还伴随肠道样症状,如腹痛,恶心,呕吐和腹泻。此外,流感病毒还会导致肠道菌群功能失调,进而诱导食欲不振。
肠道是人体最大的免疫器官,若肠道菌群失调,则会损害机体固有免疫和适应性免疫功能,降低机体对流感病毒的清除作用。长期肠道菌群紊乱,出现反复性呼吸道感染的风险更高,同时免疫功能下降更为显著。流感病毒主要通过以下几种机制影响肠道菌群的改变。流感病毒感染作为重要的应激条件,会导致肠道环境改变,如肠道组织中游离羧基被氧化,导致ATP含量迅速下降,多种酶活性降低,直接或间接引起菌群含量变化。流感病毒感染会间接影响食欲,减少肠道蠕动,进而影响胃肠道粘膜屏障功能,增加肠道菌群紊乱风险。流感病毒还可能通过减少短链脂肪酸的产生,破坏肠道固有屏障,继而导致肠道菌群紊乱。目前既具有抗流感作用又可调理流感恢复期肠道菌群的中药组合物未见相关报道。
发明内容
本发明提供了一种调理肠道菌群的中药组合物及其制备方法和应用,该中药组合物可缓解流感引起的各种症状,同时对流感恢复期引起的肠道菌群失衡有显著调理作用。
为解决上述技术问题,本发明提供了以下技术方案:
本发明提供一种调理肠道菌群的中药组合物,包括如下重量份组分:栀子5~15份、淡豆豉10~25份、紫苏子5~15份、白芥子5~15份、莱菔子5~15份、半夏5~15份、厚朴5~15份、茯苓8~18份、生姜1~10份、苏叶5~15份、蒲公英10~20份、鱼腥草15~25份、黄芩1~10份、桔梗1~10份、红景天10~20份、葛根8~15份、板蓝根10~20份、火麻仁12~25份、火炭母20~40份、陈皮2~10份、羌活5-10份。
优选的,所述中药组合物包括如下重量份组分:栀子9份、淡豆豉18份、紫苏子9份、白芥子9份、莱菔子9份、半夏9份、厚朴9份、茯苓12份、生姜3.5份、苏叶9份、蒲公英15份、鱼腥草18份、黄芩6份、桔梗5份、红景天15份、葛根12份、板蓝根15份、火麻仁18份、火炭母30份、陈皮4.5份、羌活7.5份。
本发明提供所述中药组合物的制备方法,包括如下步骤:按配方比例称量栀子、淡豆豉、紫苏子、白芥子、莱菔子,半夏、厚朴、茯苓、生姜、苏叶、蒲公英、鱼腥草、黄芩、桔梗、红景天、葛根、羌活、板蓝根、火麻仁、火炭母、陈皮,加水煎煮,过滤取滤液、灌装、灭菌。
优选的,所述水的加入量为药材的5~10倍。
优选的,所述煎煮温度为90~99℃,煎煮时间为0.5~3h。
优选的,所述煎煮次数为1~4次。
本发明提供所述中药组合物在制备治疗流行感冒药物中的应用。
本发明提供所述中药组合物在制备调理流行感冒引起的肠道菌群失衡的药物中的应用。
与现有技术相比,本发明具有如下有益效果:
本发明中药组合物以栀子、淡豆豉为君,主要针对咽痒、心中懊恼之症状;以紫苏子、白芥子、莱菔子、半夏、茯苓、生姜、苏叶、桔梗、陈皮为臣,以上药味兼顾调整三焦气机之升降,对病毒感染后上呼吸道及胃肠道皆有缓解作用;以蒲公英、板蓝根、鱼腥草、黄芩、红景天、火麻仁为佐,以上药味皆加强抗病毒消炎及改善血氧循环;以葛根、火炭母、厚朴、羌活为使,以上三药味有升清降浊之意。上述药味配伍之后共奏缓解流感引起的失眠,胃痛,胃胀,头痛,头晕,食欲下降,咳嗽,恶心呕吐,咽痒咽痛,腹泻,便秘等症状,同时还具有调理流感恢复期患者肠道菌群的功效,最终具有治疗流感以及其后遗症的效果。
本发明所述中药组合物所对症状与现在所提出的“新型冠状病毒感染”“脑雾”表现的症状类同。故亦可推广至因咳嗽难忍、夜不成眠、身热心烦、虚烦不得眠、或心中懊怀,症状反复的新型冠状病毒感染患者。总之,该中药组合物对流感后期恢复阶段患者有显著疗效,可调节流感引起的肠道菌群失调。本发明配伍合理,简单易行,所选中药材多为药食同源中药,不良反应小,可供病人长期使用。
附图说明
图1在属水平,接受中药组合物治疗前后top15的肠道菌群相对丰度平均值。
图2在种水平,接受中药组合物治疗前后top15的肠道菌群相对丰度平均值。
图3接受中药组合物治疗前后菌群α多样性(chao1指数)。
图4接受中药组合物治疗前后菌群β多样性(NMDS)。
图5Metastat差异分析。
图6PICRUSt2功能分析。
具体实施方式
本发明提供了一种调理肠道菌群的中药组合物,包括如下重量份组分:栀子5~15份、淡豆豉10~25份、紫苏子5~15份、白芥子5~15份、莱菔子5~15份、半夏5~15份、厚朴5~15份、茯苓8~18份、生姜1~10份、苏叶5~15份、蒲公英10~20份、鱼腥草15~25份、黄芩1~10份、桔梗1~10份、红景天10~20份、葛根8~15份、板蓝根10~20份、火麻仁12~25份、火炭母20~40份、陈皮2~10份、羌活5~10份;优选的所述中药组合物包括如下重量份组分:栀子9份、淡豆豉18份、紫苏子9份、白芥子9份、莱菔子9份、半夏9份、厚朴9份、茯苓12份、生姜3.5份、苏叶9份、蒲公英15份、鱼腥草18份、黄芩6份、桔梗5份、红景天15份、葛根12份、板蓝根15份、火麻仁18份、火炭母30份、陈皮4.5份、羌活7.5份。本发明若无特殊说明,所用的中药材均为本领域技术人员熟知的市场商品。
在本发明中,所述中药组合物以栀子、淡豆豉为君,栀子既能上入心胸清透郁热以除烦,又可导火下行以除热,淡豆豉俱轻,辛凉宣散,透邪畅中,既能宣泄胸中郁热而助栀子除烦,又能开壅散满而和胃,以上两味药对咽痒、心中懊恼之症状有作用;以紫苏子、白芥子、莱菔子、半夏、茯苓、生姜、苏叶、桔梗、陈皮为臣,以上药味兼顾调整三焦气机之升降,对病毒感染后上呼吸道及胃肠道皆有缓解作用;以蒲公英、板蓝根、鱼腥草、黄芩、红景天、火麻仁为佐,以上药味皆加强抗病毒消炎及改善血氧循环;以葛根、火炭母、厚朴、羌活为使,以上三药味有升清降浊之意。上述药味配伍之后共奏缓解流感引起的失眠,胃痛,胃胀,头痛,头晕,食欲下降,咳嗽,恶心呕吐,咽痒咽痛,腹泻,便秘等症状,同时还具有调理流感恢复期患者肠道菌群的功效,最终具有治疗流感以及其后遗症的效果。
本发明提供所述中药组合物的制备方法,包括如下步骤:按配方比例称量栀子、淡豆豉、紫苏子、白芥子、莱菔子,半夏、厚朴、茯苓、生姜、苏叶、蒲公英、鱼腥草、黄芩、桔梗、红景天、葛根、羌活、板蓝根、火麻仁、火炭母、陈皮,加水煎煮,过滤取滤液、灌装、灭菌。本发明所述水的加入量为药材的5~10倍。本发明所述煎煮温度为90~99℃,优选为97~98℃;所述煎煮时间为0.5~3h,优选为1h。本发明所述煎煮次数为1~4次,优选为2~3次。本发明除首次煎煮外,其余煎煮均是将过滤后的药渣加水进行煎煮。本发明上述药材为中药饮片。本发明所述灌装的量为200~300mL/包。
本发明提供所述中药组合物在制备治疗流行感冒药物中的应用。本发明所述中药组合物主要缓解流感病毒引起的失眠、胃痛、胃胀、头痛、头晕、食欲下降、咳嗽、恶心呕吐、咽痒咽痛、腹泻、便秘等症状。
本发明还提供所述中药组合物在制备调理流行感冒引起的肠道菌群失衡的药物中的应用。
在本发明中,若无特殊说明,所有的原料组分均为本领域技术人员熟知的市售商品。
下面将结合本发明中的实施例,对本发明中的技术方案进行清楚、完整地描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种调理肠道菌群的中药组合物,由如下重量份组分组成:栀子9份、淡豆豉18份、紫苏子9份、白芥子9份、莱菔子9份、半夏9份、厚朴9份、茯苓12份、生姜3.5份、苏叶9份、蒲公英15份、鱼腥草18份、黄芩6份、桔梗5份、红景天15份、葛根12份、板蓝根15份、火麻仁18份、火炭母30份、陈皮4.5份、羌活7.5份。
中药组合物的制备方法包括如下步骤:按上述配方比例称量上述药味的中药材饮片,加入8倍量水,98℃热水煎煮1h,过滤取滤液;将过滤后的药渣加入7倍量水重复煎煮1次,98℃热水煎煮1h,取滤液;合并两次滤液,罐装(250mL/包),灭菌。
实施例2
一种调理肠道菌群的中药组合物,由如下重量份组分组成:栀子15份、淡豆豉25份、紫苏子15份、白芥子15份、莱菔子15份、半夏15份、厚朴15份、茯苓18份、生姜5.5份、苏叶15份、蒲公英20份、鱼腥草25份、黄芩9份、桔梗8份、红景天20份、葛根15份、板蓝根20份、火麻仁25份、火炭母40份、陈皮5.5份、羌活5份。
中药组合物的制备方法包括如下步骤:按上述配方比例称量上述药味的中药材饮片,加入10倍量水,97℃热水煎煮1.5h,过滤取滤液;将过滤后的药渣加入8倍量水重复煎煮1次,95℃热水煎煮1.5h,取滤液;合并两次滤液,罐装(250mL/包),灭菌。
实施例3
一种调理肠道菌群的中药组合物,由如下重量份组分组成:栀子5份、淡豆豉10份、紫苏子5份、白芥子5份、莱菔子5份、半夏5份、厚朴5份、茯苓8份、生姜2份、苏叶5份、蒲公英10份、鱼腥草15份、黄芩2份、桔梗2份、红景天10份、葛根8份、板蓝根10份、火麻仁12份、火炭母20份、陈皮2份、羌活10份。
中药组合物的制备方法包括如下步骤:按上述配方比例称量上述药味的中药材饮片,加入5倍量水,98℃热水煎煮1.5h,过滤取滤液;将过滤后的药渣加入8倍量水重复煎煮1次,98℃热水煎煮1h,取滤液;合并两次滤液,罐装(250mL/包),灭菌。
实施例4临床试验
1.病例纳入标准
流感恢复期患者诊断标准:具有失眠,胃痛,胃胀,头痛,头晕,食欲下降,咳嗽,恶心呕吐,咽痒咽痛,腹泻,便秘等症状。自愿受试,按时服药,定期复诊。
2.排除标准
合并有肝肾、心脑血管等原发性疾病,精神病患者;近3个月内使用过抗生素者;未按规定服药,无法判定疗效者;资料不全等影响疗效或安全性判定者。
3.临床验证
对纳入的18例流感恢复期患者给予实施例1制备的中药组合物治疗,组方250mL/次,一日1次;服用1周为1个疗程。收集用药前后的粪便样本用于肠道菌群的检测。
3.1疗效判定方法
服用中药组合物后,判定标准为:痊愈:患者各种临床症状明显消失;显效:患者两种以上症状明显改善;无效:症状无改善或病情加重。
3.2肠道菌群检测及分析方法
收集流感病毒感染患者用药治疗前后的粪便样品于粪便保存液中,并于24h内送至实验室置于-80℃保存。使用Shoreline Biome公司的配套试剂盒提取和扩增粪便样本中的微生物DNA,经过质控后构建测序文库。基于PacBio Sequel三代测序平台和16S-ITS-23S全长扩增子方法测序方案进行测序。原始测序下机数据经过拆分和质控后,使用DADA2推断高精度的扩增序列变体(ASV),然后在门、纲、目、科、属、种分类学水平上进行物种注释。
基于QIIME2平台和R分析工具包,进一步进行菌群组成和结构分析,比较治疗前后肠道菌群的相对丰度特征。通过α多样性分析(Alpha diversity),构建样品的alpha稀疏曲线,对Observed species、Chao1、Ace、Simpson和Shannon指数进行统计分析。通过β多样性分析(Beta diversity)评估组间的菌群组成和结构差异,首先计算样品间的Bray-curtis距离,再进行主坐标分析(PCoA)、主成分分析(PCA)、无度量多维尺度分析(NMDS);使用Metastat、ANCOM和LEfSe进行差异分析,以在不同分组间寻找潜在的生物标志物;使用PICRUSt2进行功能预测分析,深入研究不同样品中的群落功能。
4.结果
在属水平和种水平比较相对丰度排名前15的物种,结果显示,与Baseline组(治疗前)相比,Treatment组(治疗后)提高了两个属Bacteroides和Longibaculum的相对丰度平均值,降低了Phascolarctobacterium、Fusobacterium和Klebsiella等属的相对丰度平均值(图1)。同时,在种水平,Treatment组)中Bacteroides_vulgatus和Longibaculum_sp._KGMB06250的相对丰度平均值高于Baseline组(图2)。α多样性结果显示,Treatment组的Chao1指数大于Baseline组,反映了Treatment组具有更大的物种丰富度(图3)。β多样性的NMDS结果显示stress<0.2,两组之间的菌群结构存在一定的差异,表明制备的中药组合物具有一定的肠道菌群调节功能(图4)。进一步研究中药组合物调节肠道菌群过程中,使用Metastat进行差异分析,结果显示Treatment组中的Longibaculum_sp._KGMB06250可能作为潜在的生物标志物(图5)。PICRUSt2功能分析结果显示,Baseline组和Treatment组在KEGG pathway中的灵菌红素生物合成(Prodigiosinbiosynthesis)和烟酸盐和烟酰胺代谢(Nicotinate and nicotinamide metabolism)存在显著差异(图6)。综上所述,该中药组合物可以通过增加有益菌Longibaculum_sp._KGMB06250的相对丰度,同时降低有害菌Phascolarctobacterium、Fusobacterium和Klebsiella的相对丰度,进而调节烟酸盐和烟酰胺代谢通路以达到緩解流感引起的肠道菌群失衡的效果。
实施例5典型病例
1、患者何小姐为澳门新型冠状病毒感染群组中一名密切接触者,被隔离于酒店中,初始1~3天只有少许咽干痛,第4天核酸阳性,开始症状加重,咳嗽,咽痛咽痒,予以实施例1制备的中药组合物(冲剂)早晚各一次服用,每次1包,用药后第二天发热38.5℃,开始出现肠胃不适,其他症状同前,第三天退热,咽痛症状緩解,伴有少许咳嗽,腹泻,予以一天一次服药,一次1包,第四天抗原测试阴性,各症状已经基本缓解,无不适。5天后再查CT值为35.8℃,康复可以出院。
期间患者的3个小孩同时被隔离,当发现患者阳性后也服用该中药组合物,数天后2小孩核酸阳性及伴上呼吸道感染症状,1个少许咳嗽(使用中药组合方后,会表现出抗病毒反应,存在一定上呼吸道症状或弱阳性表现,目的是通过气道排异反应(咳嗽,排痰)将吸入气道的病毒排放出去),服药4天后恢复阴性,上呼吸道症状有所缓解緩解。
由该典型病例可知,患者核酸阳性后,即时用药后3~4皆能恢复阴性。
2、多个患者(廖先生,廖太,凌小姐等人)于5月分别离开澳门前往泰国旅游,长时间密切接触阳性病人,第二天皆有感咽部不适,即服用实施例1制备的中药组合物,一天两次,每次1包,2~3天后咽部症状缓解并伴有腹泻症状,后自测多次抗原测试结果阴性。
由该典型病例可知,根据观察众多个患者,病毒感染后咽喉部会很快出现痒痛等症状,此时病毒有3~4天表现为易清理消除,因此,患者多次密切接触阳性病人后,只要及时用药,将会断绝病毒感染加重。
3、患者小孩(张小朋友,6岁)曾有过流感病毒感染病史,用西药治疗过后缓解约半年余,后一直伴有少许咽痒症状,近期诉出现肩颈抽动症状,喉咙不断重复发出异常声音,西医诊断为抽动症。来诊后予以实施例1制备的中药组合物后,咳嗽明显增加,有痰及少许腹泻症状(“愈病的反应”),服药2周后喉咙异声减少,抽动少,咳嗽少许,再服约3周后以上症状全部緩解。该病例服药出现咳嗽增加、有痰或少许腹泻症状是因为气道深处痰液很难排出,下呼吸道患者表现为反复咳嗽,通过化痰,将气道内炎症或者外界因素刺激分泌的粘液排出体外。故服用该中药组合物向上可刺激气道排异反应,从根源解决咳嗽问题;向下可纠正人体脏腑之气的偏盛偏衰,提高脾胃功能,使得沉积在体内的水湿浊邪通过下利(腹泻)的方式排出体外,这是人体“愈病的反应”。
由该典型病例可知,病毒感染可以长期留在身体内影响免疫系統,尤其是在上呼吸道,长期会影响身体多处气血循环障碍,而诱发抽动症状,因此,予以本中药组合物处理气管处的根本症状,使身体气血循环恢复正常而缓解有关问题。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (8)
1.一种调理肠道菌群的中药组合物,其特征在于,原料药由如下重量份组分组成:栀子5~15份、淡豆豉10~25份、紫苏子5~15份、白芥子5~15份、莱菔子5~15份、半夏5~15份、厚朴5~15份、茯苓8~18份、生姜1~10份、苏叶5~15份、蒲公英10~20份、鱼腥草15~25份、黄芩1~10份、桔梗1~10份、红景天10~20份、葛根8~15份、板蓝根10~20份、火麻仁12~25份、火炭母20~40份、陈皮2~10份、羌活5-10份。
2.如权利要求1所述的中药组合物,其特征在于,原料药由如下重量份组分组成:栀子9份、淡豆豉18份、紫苏子9份、白芥子9份、莱菔子9份、半夏9份、厚朴9份、茯苓12份、生姜3.5份、苏叶9份、蒲公英15份、鱼腥草18份、黄芩6份、桔梗5份、红景天15份、葛根12份、板蓝根15份、火麻仁18份、火炭母30份、陈皮4.5份、羌活7.5份。
3.如权利要求1或2所述中药组合物的制备方法,其特征在于,包括如下步骤:按配方比例称量栀子、淡豆豉、紫苏子、白芥子、莱菔子,半夏、厚朴、茯苓、生姜、苏叶、蒲公英、鱼腥草、黄芩、桔梗、红景天、葛根、羌活、板蓝根、火麻仁、火炭母、陈皮,加水煎煮,过滤取滤液、灌装、灭菌。
4.如权利要求3所述的制备方法,其特征在于,所述水的加入量为药材的5~10倍。
5.如权利要求3所述的制备方法,其特征在于,所述煎煮温度为90~99℃,煎煮时间为0.5~3h。
6.如权利要求3所述的制备方法,其特征在于,所述煎煮次数为1~4次。
7.如权利要求1所述的中药组合物在制备缓解新型冠状病毒引起的症状的药物中的应用。
8.如权利要求1所述的中药组合物在制备调理流行感冒引起的肠道菌群失衡的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311281481.3A CN117100833B (zh) | 2023-10-07 | 2023-10-07 | 一种调理肠道菌群的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311281481.3A CN117100833B (zh) | 2023-10-07 | 2023-10-07 | 一种调理肠道菌群的中药组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117100833A CN117100833A (zh) | 2023-11-24 |
CN117100833B true CN117100833B (zh) | 2024-06-07 |
Family
ID=88800260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311281481.3A Active CN117100833B (zh) | 2023-10-07 | 2023-10-07 | 一种调理肠道菌群的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117100833B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1608654A (zh) * | 2003-10-17 | 2005-04-27 | 徐万富 | 一种治疗肺内感染及防治非典型肺炎的中药 |
CN108653574A (zh) * | 2018-08-13 | 2018-10-16 | 三株福尔制药有限公司 | 益生菌发酵的抗病毒组合物及其制备方法和应用 |
CN116585441A (zh) * | 2023-03-10 | 2023-08-15 | 巫祯来 | 一种用于防治新型冠状病毒感染的中药组合物及其制备方法 |
CN116785387A (zh) * | 2023-07-12 | 2023-09-22 | 淳安县中医院 | 一种中药组合物及其在制备呼吸道疾病药物中的用途 |
-
2023
- 2023-10-07 CN CN202311281481.3A patent/CN117100833B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1608654A (zh) * | 2003-10-17 | 2005-04-27 | 徐万富 | 一种治疗肺内感染及防治非典型肺炎的中药 |
CN108653574A (zh) * | 2018-08-13 | 2018-10-16 | 三株福尔制药有限公司 | 益生菌发酵的抗病毒组合物及其制备方法和应用 |
CN116585441A (zh) * | 2023-03-10 | 2023-08-15 | 巫祯来 | 一种用于防治新型冠状病毒感染的中药组合物及其制备方法 |
CN116785387A (zh) * | 2023-07-12 | 2023-09-22 | 淳安县中医院 | 一种中药组合物及其在制备呼吸道疾病药物中的用途 |
Non-Patent Citations (1)
Title |
---|
雾化吸入加味二陈汤合三子养亲汤治疗痰湿蕴肺型咳嗽临床疗效观察;李昌彬 等;亚太传统医药;20140131;10(02);93-94 * |
Also Published As
Publication number | Publication date |
---|---|
CN117100833A (zh) | 2023-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100546620C (zh) | 一种治疗呼吸道疾病的中药及其制备方法 | |
CN105362906A (zh) | 一种治疗儿童脾胃虚弱、饮食积滞证的中药及其制备方法 | |
CN103520395A (zh) | 一种治疗肺癌的中药组合物 | |
CN103961614B (zh) | 用于治疗呼吸系统疾病的中药组合物及其制备方法和用途 | |
CN111569010B (zh) | 一种中药组合物及其在制备治疗新冠肺炎的药物中的应用 | |
CN105126030B (zh) | 一种辅助抗肺癌的壮药组合物 | |
CN101322749B (zh) | 一种治疗风热感冒的中药口服液及其制备方法 | |
CN117100833B (zh) | 一种调理肠道菌群的中药组合物及其制备方法和应用 | |
CN110812455A (zh) | 一种治疗儿童厌食、偏食等病症的液体口服制剂及其制备方法和用途 | |
CN113476562B (zh) | 一种组合物及其制备方法和用途 | |
CN105012770A (zh) | 一种保健饮料及其制备方法 | |
CN103405722B (zh) | 一种预防和治疗小儿咳嗽的中药制剂 | |
CN104984311A (zh) | 一种治疗小儿哮喘的中药组合物及其制备方法 | |
CN105343503B (zh) | 一种治疗咽喉炎的药物组合物及其应用 | |
CN104491637B (zh) | 一种治疗感冒后咳嗽的复方组合药物及其制备方法与应用 | |
CN111346172B (zh) | 一种提高免疫力的药物组合物 | |
CN116350741B (zh) | 一种治疗糖尿病胃轻瘫的中药组合物及其制备方法 | |
CN115998824B (zh) | 一种祛湿解毒的中药组合物及其制备方法和应用 | |
CN116712515B (zh) | 一种治疗发热的中药组合物及其制备方法和用途 | |
CN1132611C (zh) | 治疗慢性喉炎、声带小结的药物及其颗粒剂的制备方法 | |
CN103399121A (zh) | 一种中药宁心安神制剂的质量控制方法 | |
CN115317577B (zh) | 一种治疗小儿咳嗽的中药组合物 | |
CN109091633B (zh) | 一种用于小儿反复呼吸道感染的组合物及制法和应用 | |
CN108888731B (zh) | 一种止咳化痰的药物组合物 | |
CN107362247A (zh) | 一种具有治疗老年人感染后咳嗽的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |